Diagnosis and management of malignant germ cell ovarian tumors in young females

International Journal of Gynecology and Obstetrics

Volumn 55, Issue 1, 1996, Pages 1-10

  Zalel, Y ^a   Piura, B ^b   Elchalal, U ^c   Czernobilsky, B ^a   Antebi, S ^c   Dgani, R ^a  

^a KAPLAN HOSPITAL   (Israel)

^b BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

^c HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

Germ cell tumors; Management; Young females

Indexed keywords

ALPHA FETOPROTEIN; ANTINEOPLASTIC AGENT; BLEOMYCIN; CHORIONIC GONADOTROPIN; CISPLATIN; ETOPOSIDE; TUMOR MARKER;

AGE; CANCER RECURRENCE; DYSGERMINOMA; EARLY DIAGNOSIS; EMBRYONAL CARCINOMA; FEMALE; FEMALE FERTILITY; GERM CELL TUMOR; HUMAN; OVARY CANCER; PRIORITY JOURNAL; PROGNOSIS; REVIEW; TERATOMA; YOLK SAC TUMOR;

EID: 0039456896     PISSN: 00207292     EISSN: None     Source Type: Journal    
DOI: 10.1016/0020-7292(96)02719-1     Document Type: Review

References (78)

1. [1] Breen JL, Maxon WS. Ovarian tumors in children and adolescents. Clin Obstet Gynecol 1977; 20: 607.
2. [2] Groeber WR. Ovarian tumors during infancy and childhood. Am J Obstet Gynecol 1963; 86: 1027.
3. [3] Norris HJ, Jensen RD. Relative frequency of ovarian neoplasms in children and adolescents. Cancer 1972; 30: 713.
4. [4] Piura B, Dgani R, Zalel Y, Nemet D, Yanay-Inbar I, Cohen Y, et al. Malignant germ cell tumors of the ovary: a study of 20 cases. J Surg Oncol 1995; 59: 155.
5. [5] Kobayashi M. Use of diagnostic ultrasound in trophoblastic neoplasms and ovarian tumors. Cancer 1976; 38: 441.
6. [6] Serov SF, Scully RE, Subin LH. Histological typing of ovarian tumors. In: International histological classification of tumors, no. 9. Geneva: World Health Organization, 1973.
7. [7] Kurman RJ, Norris HJ. Malignant mixed germ cell tumors of the ovary, a clinical and pathologic analysis of 30 cases. Obstet Gynecol 1976; 48: 579.
8. [8] Krepart G, Smith JP, Rutledge F, Delclos L. The treatment for dysgerminoma of the ovary. Cancer 1978; 41: 986.
9. [9] Asadourian LA, Taylor HB. Dysgerminoma: an analysis of 105 cases. Obstet Gynecol 1969; 33: 370.
10. [10] Gallion HH, van Nagell Jr JR, Donaldson ES, Powel DE. Ovarian dysgerminoma: report of seven cases and review of the literature. Am J Obstet Gynecol 1988; 158: 591.
11. [11] Andrews J. Streak gonads and the Y chromosome. J Obstet Gynaecol Br Commonwlth 1971; 78: 448.
12. [12] Berek JS, Hacker NF. Practical gynecologic oncology. Baltimore, MD: Williams and Wilkins, 1989: 368.
13. [13] Scully RE. Tumors of the ovary and maldeveloped gonads. In: Atlas of tumor pathology. Fascicle 16. Washington, DC: AFIP, 1979.
14. [14] Navot D, Laufer N, Kopolovic J, Rabinovitz R, Birkenfeld I, Lewin I, et al. Artificially induced endometrial cycles and establishment of pregnancies in the absence of ovaries. N Engl J Med 1986; 314: 806.
15. [15] Teilum G. Endodermal sinus tumor of the ovary and testis. Cancer 1959; 12: 1092.
16. [16] Kurman RJ, Norris HJ. Endodermal sinus tumor of the ovary: a clinical and pathologic analysis of 71 cases. Cancer 1976; 38: 2404.
17. [17] Morris HHB, La Vecchia C, Draper GJ. Endodermal sinus tumor and embryonal carcinoma of the ovary in children. Gynecol Oncol 1985; 21: 7.
18. [18] Kurman RJ, Norris HJ. Embryonal carcinoma of the ovary. A clinicopathologic entity distinct from endodermal sinus tumor resembling embryonal carcinoma of the adult testis. Cancer 1976; 38: 2420.
19. [19] Gershenson DM, Del Junco G, Silva EG, Copeland LJ, Taylor Wharton J, Rutledge FN. Immature teratoma of the ovary. Obstet Gynecol 1986; 68: 624.
20. [20] Norris HJ, Zirkin HJ, Benson WL. Immature (malignant) teratoma of the ovary. A clinical and pathologic study of 58 cases. Cancer 1976; 37: 2359.
21. [21] Gershenson DM, Del Junco G, Copeland LJ, Rutledge FN. Mixed germ cell tumors of the ovary. Obstet Gynecol 1984; 64: 200.
22. [22] Jacobs AJ, Newland JR, Green RK. Pure choriocarcinoraa of the ovary. Obstet Gynecol Surv 1982; 37: 603.
23. [23] Axe SR, Klein VR, Woodruff JD. Choriocarcinoma of the ovary. Obstet Gynecol 1985; 66: 111.
24. [24] Kurman RJ, Norris HJ. Malignant germ cell tumors of the ovary. Hum Pathol 1977; 8: 551.
25. [25] Gerbie MV, Brewer JI, Tamini H. Primary choriocarcinoma of the ovary. Obstet Gynecol 1975; 46: 720.
26. [26] Turner HB, Douglas WM, Gladding TC. Choriocarcinoma of the ovary. Obstet Gynecol 1964; 24: 918.
27. [27] Goldstein DP. Case records of the Massachusetts General Hospital Case-15 1977. N Engl J Med 1977; 296: 926.
28. [28] Brewer JI, Eckman TR, Dolkart RE. Gestational trophoblastic disease. Am J Obstet Gynecol 1971; 109: 1335.
29. [29] Donaldson ES, van Nagell JR, Pursell S, Gay EC. Multiple biochemical markers in patient with gynecologic malignancies. Cancer 1980; 45: 948.
30. [30] Mohaghan P. Tumor markers and testicular cancer. Serono symposium no. 46. In: Markers for diagnosis and monitoring of human cancer. London: Academic Press, 1982: 213-225.
31. [31] Kawata M, Sekiya S, Hatakeyama R, Takamizawa H. Neuron-specific enolase as a serum marker for immature teratoma and dysgerminoma. Gynecol Oncol 1989; 32: 191.
32. [32] Vaitukaitis JL, Braunstein GD, Ross GT. A radioimmunoassay which specifically measures human chorionic gonadotropin in the presence of human luteinizing hormone. Am J Obstet Gynecol 1972; 113: 751.
33. [33] Ayala AR, Saad A, Vasquez X, Ramirez-Weilla G, Perches RD. Human chorionic gonadotropin immunoreactivity in serum of patients with malignant neoplasms. Am J Reprod Immunol 1983; 3: 149.
34. [34] Zarabi MC, Rupani M. Human chorionic gonadotropin secreting pure dysgerminoma. Hum Pathol 1984; 15: 589.
35. [35] Dgani R, Shoham Z, Czernobilsky B, Kaftori A, Borenstein R, Lancet M. Lactic dehydrogenase, alkaline phosphatase and human chorionic gonadotropin in a pure ovarian dysgerminoma. Gynecol Oncol 1988; 30: 44.
36. [36] Gershenson DM, Copeland LJ, Del Junco G, Edwards CL, Taylor Wharton J, Rutledge FN. Second-look laparotomy in the management of malignant germ cell tumors of the ovary. Obstet Gynecol 1986; 67: 789.
37. [37] Micha JP, Kucera PR, Herman ML, Romansky S, Flamm M, Reynolds J, et al. Malignant ovarian germ cell tumors: a review of 36 cases. Am J Obstet Gynecol 1985; 152: 842.
38. [38] LaPolla JP, Fiorica JV, Turnquist D, Nicosia S, Wilson J, Cavanagh D. Successful therapy of metastatic embryonal carcinoma coexisting with gonadoblastoma in a patient with 46,XY pure gonadal dysgenesis (Swyer's syndrome), Gynecol Oncol 1990; 37: 417.
39. [39] Schwartz PE. Combination chemotherapy in the management of ovarian germ cell malignancies. Obstet Gynecol 1984; 64: 564.
40. [40] Vance RP, Geisinger KR. Pure nongestational choriocarcinoma of the ovary. Report of a case. Cancer 1985; 56: 2321.
41. [41] Romero R, Schwartz PE. Alpha fetoprotein determinations in the management of endodermal sinus tumors and mixed germ cell tumors of the ovary. Am J Obstet Gynecol 1981; 141: 126.
42. [42] Ihara T, Ohama K, Satoh H, Fujii T, Nomura K, Fujiwara A. Histologie grade and karyotype of immature teratoma of the ovary. Cancer 1984; 54: 2988.
43. [43] Barzell WB, Whitmore WF. Clinical significance of biologic markers: Memorial Hospital experience. Semin Oncol 1979; 6: 48.
44. [44] Schneider RJ, Siebert K, Passe S, Gee T, Lee BJ, Mike V, et al. Prognostic significance of serum lactic dehydrogenase in malignant lymphoma. Cancer 1980; 46: 139.
45. [45] Awais GM. Dysgerminoma and serum lactic dehydrogenase levels. Obstet Gynecol 1983; 61: 99.
46. [46] Zondag HA. Enzyme activity in dysgerminoma and seminoma: a study of lactic dehydrogenase isoenzymes in malignant diseases. Rhode Island Med J 1964; 47: 273.
47. [47] Koudstall J, Bosenbroek B, Hardonk MJ. Ovarian tumors investigated by histochemical and enzyme histochemical methods. Am J Obstet Gynecol 1968; 102: 1004.
48. [48] Kabawat SE, Bast RC Jr, Welch WR. Immunopathologic characterization of a monoclonal antibody that recognizes common surface antigens in human ovarian tumors of serous, endometrioid and clear core type. Am J Clin Pathol 1983; 79: 98.
49. [49] Kabawat SE, Bast RC Jr, Bhan A. Tissue distribution of a coelomic epithelium related antigen recognized by the monoclonal antibody OC 125. Lab Invest 1983; 48: 42A.
50. [50] Altaras MM, Goldberg GL, Lewin W, Darge L, Bloch B, Smith JA. The value of cancer antigen-125 as a tumor marker in malignant germ cell tumors of the ovary. Gynecol Oncol 1986; 25: 150.
51. [51] Anstey A, Gowers L, Vass A, Robson AO. Ovarian dysgerminoma presenting with hypercalcaemia. Case report and review of the literature. Br J Obstet Gynaecol 1990; 97: 641.
52. [52] Afridi MA, Vongtama V, Tsukada Y, Piver MS. Dysgerminoma of the ovary: radiation therapy for recurrence and metastases. Am J Obstet Gynecol 1976; 120: 196.
53. [53] Gershenson DM, Morris M, Cangir A, Kavanagh JJ, Stringer CA, Edwards CL. Treatment of malignant germ cell tumors of the ovary with bleomycin, etoposide and cisplatin (BEP). J Clin Oncol 1990; 8: 715.
54. [54] Sivanesaratnam V, Sen DK, Peh SC. Cure of stage IV endodermal sinus tumor of the ovary with pulsed cyclophosphamide therapy. Gynecol Oncol 1986; 25: 133.
55. [55] Gershenson DM, Taylor Wharton J, Kline RC, Larson DM, Kavanagh JJ, Rutledge FN. Chemotherapeutic complete remission in patients with metastatic ovarian dysgerminoma. Potential for cure and preservation of reproductive capacity. Cancer 1986; 58: 2594.
56. [56] Javaheri G, Lifschez A, Valle J. Pregnancy following removal of and long-term chemotherapy for ovarian malignant teratoma. Obstet Gynecol 1983; 61: 85.
57. [57] Gershenson DM, Del Junco G, Herson J, Rutledge FN. Endodermal sinus tumors of the ovary: the M.D. Anderson experience. Obstet Gynecol 1983; 61: 194.
58. [58] Gershenson DM, Morris M, Cangir A, Kavanagh JJ, Stringer CA, Edwards CL. Treatment of malignant germ cell tumors of the ovary with bleomycin, etoposide and cisplatin (BEP). J Clin Oncol 1990; 8: 715.
59. [59] Gershenson DM. Update on malignant ovarian germ cell tumors. Cancer 1993; 71 Suppl: 1581.
60. [60] Thomas GM, Dembo AJ, Hacker NF, DePetrillo AD. Current therapy for dysgerminoma of the ovary. Obstet Gynecol 1987; 70: 268.
61. [61] Jolles CJ, Karayianis S, Smotkin D, Delia JE. Advanced ovarian dysgerminoma with cure of tumor persistent in meninges. Gynecol Oncol 1989; 33: 389.
62. [62] Williams SD, Blessing JA, Moore DH, Homesley HD, Adcock L. Cisplatin, vinblastine and bleomycin in advanced and recurrent ovarian germ cell tumors. Ann Intern Med 1989; 111: 22.
63. [63] Williams SD, Birch R, Einhorn LH, Irwin L, Greco FA, Loehrer PJ. Treatment of disseminated germ-cell tumors with cisplatin, bleomycin and either vinblastine or etoposide. N Engl J Med 1987; 316: 1435.
64. [64] Gershenson DM, Kavanagh JJ, Copeland LJ, Del Junco GD, Cangir A, Saul PB. Treatment of malignant non-dysgerminomatous germ cell tumors of the ovary with vinblastine, bleomycin and cisplatin. Cancer 1986; 57: 1731.
65. [65] Wong LC, Ngan HYS, Ma HK. Primary treatment with vincristine, dactinomycin and cyclophosphamide in non-dysgerminomatous germ cell tumor of the ovary. Gynecol Oncol 1989; 34: 155.
66. [66] Gershenson DM, Copeland LJ, Kavanagh JJ, Cangir A, Del Junco GD, Saul PB. Treatment of malignant non-dysgerminomatous germ cell tumor of the ovary with vincristine, dactinomycin and cyclophosphamide. Cancer 1985; 56: 2756.
67. [67] Stayton RE, Park RC, Silverberg SG, Shingleton H, Creasman WT, Blessing JA. Vincristine, dactinomycin and cyclophosphamide in the treatment of malignant germ cell tumors of the ovary: a Gynecologic Oncologic Group study (a final report). Cancer 1985; 56: 243.
68. [68] Schwartz PE, Chambers SK, Chambers JT, Kohorn E. McIntosh S. Ovarian germ cell malignancies: the Yale University experience. Gynecol Oncol 1992; 45: 26.
69. [69] Williams SD, Blessing JA, Stayton RE, Homesley H, Photopolus G. Ovarian germ cell tumors: adjuvant trials of the Gynecologic Oncology Group [abstract]. Proc Am Soc Clin Oncol 1989; 8: 150.
70. [70] Creasman WT, Soper JT. Assessment of the contemporary management of germ cell malignancies of the ovary. Am J Obstet Gynecol 1985; 153: 828.
71. [71] Williams SD, Blessing JA, Moore DH, Homesley HD, Adcock L. Cisplatin, vinblastine and bleomycin in advanced and recurrent ovarian germ-cell tumors. Ann Intern Med 1989; 11: 22.
72. [72] Nichols CR, Tricot G, Williams SD, van Besien K, Loehrer PJ, Roth BJ. Dose-intensive chemotherapy in refractory germ cell cancer: a phase I/II trial of high-dose carboplatin and etoposide with autologous bone marrow transplantation. J Clin Oncol 1989; 7: 932.
73. [73] Broun ER, Tricot G, Fox E, Loehrer PJ, Williams SD, Einhorn LH. Long term follow-up of salvage chemotherapy in relapsed and refractory germ cell tumors using high-dose carboplatin and etoposide with autologous bone marrow rescue (ABMR) [abstract]. Proc Ann Soc Clin Oncol 1991; 10: 167.
74. [74] Jacobs LJ, Harris M, Deppe G. Treatment of recurrent and persistent germ cell tumors with cisplatin, vinblastine and bleomycin. Obstet Gynecol 1982; 59: 129.
75. [75] Sessa C, Bonazzi C, Landoni F, Pecorelli S, Sartori E. Cisplatin, vinblastine and bleomycin combination chemotherapy in endodermal sinus tumor of the ovary. Obstet Gynecol 1987; 70: 220.
76. [76] DiSaia PJ, Saltz A, Kagan AR. Chemotherapeutic retroconversion of immature teratoma of the ovary. Obstet Gynecol 1977; 49: 346.
77. [77] Gershenson DM. Menstrual and reproductive function after treatment with combination chemotherapy for malignant ovarian germ cell tumors. J Clin Oncol 1988; 6: 270.
78. [78] Taylor MH, DePetrillo AD, Turner AR. Vinblastine, bleomycin and cisplatin in malignant germ cell tumors of the ovary. Cancer 1985; 56: 1341.